UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

Twelve days after GSK secured a key win in Florida, with a state court tossing expert testimony on the cancer-causing ...

British pharmaceutical group GSK on Friday welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment ...

That win closely followed a settlement in a separate Zantac prostate cancer ... personal injury case to go to trial, Chicago jurors in late May absolved GSK and Boehringer Ingelheim of fault ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn ...

Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...

Zantac does not cause any type of cancer." Two such cases previously went to trial, both ending in verdicts for the defense - one for Boehringer Ingelheim and GSK in May, and the other for GSK on ...

British pharmaceutical group GSK on Friday (Aug 16) welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment, ...